DOCSLIB.ORG

Annual Report 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2019 Experience patients telling their stories. Scan the marked images with the Xtend app to watch the videos. Annual Report 2019 Experience Adeline telling her story. Scan the image with the Xtend app to watch the video. Every day Developing cures for patients—as a science- driven organisation we strive towards converting today’s knowledge into tomorrow’s therapies. We are pushing boundaries. Millions of people, like Adeline, have hepatitis B and we are developing medicines to help them. Everywhere Bringing our products to patients—we are committed to bringing our medicines and tests rapidly and sustainably to those who need them. We are open to new ideas. Working in collaboration with healthcare systems and our partners is key to resolving critical access barriers to therapies. Everyone Benefiting people in need—motivated and skilled employees collaborate across cultures and locations to develop life-saving products. We share one purpose. An abiding dedication to high quality ensures that doctors have the backing of pioneering science to treat their patients. Doing now what patients need next We believe it’s urgent to deliver medical solutions right now—even as we develop innovations for the future. We are passionate about transforming patients’ lives. We are courageous in both decision and action. And we believe that good business means a better world. That is why we come to work each day. We commit ourselves to scientific rigour, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow. We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world. We are Roche. “I feel that I have been able to strengthen the patient’s position as a stakeholder.” Ike de Rooij-van Haaren, Consultant, Oman I moved to Basel five years ago with my husband and numbers and always asked what it meant for three sons. Just a few months later I was diagnosed individual patients such as myself. with HER2-positive breast cancer. Fortunately, I received timely treatment with two of Roche’s breast The project itself was meant to last three months. cancer medicines in my native Holland. For that, I But the team realised they could benefit more from had to leave my young boys and husband behind my journey and real-life experiences as a patient. here in what was a new place for them. Therefore, I signed a patient consultant contract and continued to work with Roche. It has been more I made up my mind while still undergoing treatment than three years now. that I wanted to give something back to Roche. The company had kindly allowed me to participate in I now live in the Middle East and this sometimes a study of one of its medicines and this inspired me poses a logistical challenge. Technology helps, but I greatly. I mentioned it to a friend who worked at try to attend meetings in person when possible. I work Roche and he came back to me with some details with the broader HER2 franchise team these days about a project aimed at putting a patient in one of and over the years have been involved in prelaunch, the brand teams to see what effect that would have launch and postlaunch activities. My role is to give and if it would change the decision-making within the patient perspective at any stage of the medicine’s the team. life cycle. I am also a member of a committee set up by Roche, where, along with other patients, we review I was nervous at first, but decided to take the plunge. topics that teams request advice on, such as patient I realised that I just had to be myself and share my information materials and clinical trials. experiences. It took a couple of meetings with the brand team to get used to each other. The team I got I feel that I have been able to strengthen the patient’s to work with was working on the same breast cancer position as a stakeholder. It has been difficult to medicine that I had been treated with. They were engage with patients at times and this makes it hard curious to hear my experience and therefore I felt to understand their real needs. Now, with efforts such confident to share my opinions. From the beginning as the one I am involved in, business teams are really I could see the impact of having the actual patient’s looking at ways to give this important stakeholder a voice in the room. I was never interested in the stronger voice in the work they do. Experience Ike telling her story. Scan the images with the Xtend app to watch the video. Innovation—it’s in our DNA We have always worked across disciplines and geographies to drive scientific discovery and redefine what is possible to improve patients’ lives. We are working on understanding how diseases differ also the world leader in the in vitro diagnostics down to molecular level. So we can develop new business. This track record allows us to build lasting tests and medicines that prevent, diagnose and treat and meaningful partnerships across the world with diseases, and bring them to the patients who need research academia and public healthcare institutions. them. With our combined strengths in diagnostics and pharmaceuticals, our personalised healthcare The founding families continue to hold the majority strategy aims to fit the right treatment to the right voting stake in the company. This stability allows for patient. a tradition of sustainable thinking, so we can learn from setbacks and focus on lasting value for patients As the world’s largest biotech company, we develop and society. We remain dedicated to the highest breakthrough medicines, improving the standard standards of quality, safety and integrity. Our legacy of care across oncology, immunology, infectious is based on respect for the individual as well as the diseases, ophthalmology and neuroscience. We are communities and the world we live in. Experience more about Roche. Scan the world map with the Xtend app to watch the video. Key figures Highlights CHF 61,466 million Driving growth Group sales +9%* With CHF 5.4 billion incremental sales, medicines launched since 2012 drive growth and rejuvenation of our product portfolio CHF 22,479 million Read more on page 24 Core operating profit +11% Treating rare cancer Rozlytrek approved to treat rare form of lung CHF 9.00 cancer that occurs in 1–2% of patients only Dividend Read more on page 35 CHF 11,696 million Launching cobas pro R & D core investments +6% Next-generation integrated Serum Work Area solutions improve efficiency and shorten results delivery 37 million patients Read more on page 26 treated with Roche medicines Contributing to sustainability Roche ranked amongst most sustainable 32 Roche medicines healthcare companies in the Dow Jones on the WHO Model List of Essential Medicines Sustainability Indices 97,735 employees** worldwide North America Europe 26,176 employees 42,112 employees Genentech, South San Francisco, US ( ) Basel, Kaiseraugst and Rotkreuz, Switzerland ( ) Roche Diagnostics, Indianapolis, US ( ) Mannheim and Penzberg, Germany ( ) Latin America Asia 4,682 employees 22,802 employees Chugai, Tokyo, Japan ( ) Africa Shanghai and Suzhou, China ( ) 1,258 employees Australia/New Zealand 705 employees 29 23 research and development sites in manufacturing sites in Pharmaceuticals Pharmaceuticals and Diagnostics worldwide and Diagnostics worldwide Roche Group headquarters Manufacturing sites in Pharmaceuticals and Diagnostics Largest sites based on number of employees Sales sites in Pharmaceuticals and Diagnostics Research and development sites in Pharmaceuticals and Diagnostics * All growth rates in this report are at constant exchange rates (CER; average 2018). | ** Number of employees expressed in full-time equivalents, on 31.12.2019 12 Overview 76 Environment 22 Business performance 86 Community engagement 42 Science and innovation 92 Integrity in business 58 Access to healthcare 102 Corporate Governance 68 Our people 120 Remuneration Report 12 Material topic covered in this chapter Cybersecurity Our reporting approach Roche is committed to transparent reporting and we endeavour to drive our economic, social and environmental performance with the same diligence as our financial performance. Reporting scope and boundaries all material risks and opportunities, is discussed Our financial and non- financial reporting consists annually with the Corporate Executive Committee of the Annual Report, the Finance Report and the and reviewed by the Audit Committee of the Board online report. It contains the annual financial of Directors and by the Board of Directors. The statements, consolidated financial statements and effectiveness of the Group Risk Management Process non- financial performance indicators. It covers is regularly monitored by the Group Risk Advisory all regions and divisions of the Roche Group from team, and the overall process is reviewed externally 1 January to 31 December 2019. The financial when appropriate. Risk management is embedded at reporting scope is defined and outlined in our all levels of the Group. Our Pharmaceuticals and Finance Report, and there have been no significant Diagnostics Divisions and global functions conduct changes in scope in 2019 compared to 2018. a formal risk assessment process at least once a year and must develop mitigation plans for their most GRI standards and materiality material risks. We have followed the GRI G4 guidelines (Global Reporting Initiative) since 2014, and have transitioned Read more in ‘Corporate Governance’ on page 102 to the GRI Standards in 2017. By using the GRI guidelines, we disclose the most critical impacts of We also identify long-term business sustainability our activities on the environment, society and the trends with associated risks and opportunities on economy.
Load more

Recommended publications
  • Lafargeholcim CDP Climate Change 2020
    LafargeHolcim Ltd - Climate Change 2020 C0. Introduction C0.1 (C0.1) Give a general description and introduction to your organization. Company Profile LafargeHolcim is the global leader in building materials and solutions. It is active in four business segments: Cement, Aggregates, Ready-Mix Concrete, and Solutions and Products. It was founded in mid-2015 following the merger of Lafarge S.A and Holcim Ltd. The Group has a presence in around 80 countries and has over 70 000 employees. In 2019 it recorded CHF 26.7 bn in net sales and has 286 mt of annual cement production capacity worldwide. The Group has over 2,300 plants (including over 1,400 in ready mix concrete, 649 in aggregates and 264 in cement and grinding plants). The Group has solutions and services in cement, concrete, and aggregates for the following businesses: buildings, infrastructure, distribution, oil and gas, affordable housing, and construction systems. Cement is manufactured through a large-scale, capital-and-energy-intensive process. At the core of the production process is a rotary kiln, in which limestone and clay are heated to approximately 1,450 degrees Celsius. The semi-finished product, clinker, is created by sintering. In the cement mill, gypsum is added to the clinker and the mixture is ground to a fine powder – traditional Portland cement. Other high-grade materials such as granulated blast furnace slag, fly ash, pozzolan, and limestone can be added in order to modify the properties of the cement for special uses or specific application. Aggregates include crushed stone, gravel, and sand. They can also be recycled from concrete wastes.
    [Show full text]
  • Annual Report 2018 Annual Report 2018 Lafargeholcim Is the Global Leader in Building Materials and Solutions
    Annual Report 2018 LafargeHolcim Ltd Annual Report 2018 LafargeHolcim is the global leader in building materials and solutions. We are active in four business segments: Cement, Aggregates, Ready-Mix Concrete and Solutions & Products. With leading positions in all regions of the world and a balanced portfolio between developing and mature markets, LafargeHolcim offers a broad range of high- quality building materials and solutions. LafargeHolcim experts solve the challenges that customers face around the world, whether they are building individual homes or major infrastructure projects. Demand for our materials and solutions is driven by global population growth, urbanization, improved living standards and sustainable construction. Around 75,000 people work for the company in around 80 countries. Read the online summary at LafargeHolcim is listed on the SIX Swiss Exchange Paris, France www.lafargeholcim.com and on Euronext Paris, and is a member of Employees at one of our worksites for the Dow Jones Sustainability Indices (DJSI) the Grand Paris Express, the largest infrastructure The Sustainability Report complements this report. European Index. project in Europe (see page 36). It presents more detail on our sustainability achievements as well as progress against our sustainability strategy. Contents In this report Page Overview Chairman statement 14 12 —25 CEO letter to shareholders 16 Meet the leadership team 18 Market 20 Strategy 2022 – “Building for Growth” 22 Business Largest footprint in the industry 28 26 — 87 review Business segments
    [Show full text]
  • Proposed Spin-Off of Alcon
    PROPOSED SPIN-OFF OF ALCON | A Proposed Spin-off of Alcon Shareholder Information Brochure General Meeting of Shareholders of Novartis AG February 28, 2019 Brochure dated as of January 30, 2019 B | PROPOSED SPIN-OFF OF ALCON Important Information This information brochure has been prepared exclusively for the We urge future holders of Alcon Shares to read the Form 20-F on shareholders of Novartis AG and holders of Novartis American file with the SEC or the SIX listing prospectus, once available, and Depositary Receipts (“ADRs”) in connection with the spin-off of Alcon familiarize themselves with the entire content, including the risk factors. proposed to the annual general meeting of Novartis shareholders to be held on February 28, 2019 (the “General Meeting”). The information set out herein and in any related materials is subject to updating, completion, revision, verification and/or amendment. This brochure is not an offer to sell or a solicitation of offers to Neither Novartis AG nor Alcon Inc. nor any of their affiliates or their purchase or subscribe for shares in Novartis AG or Alcon Inc. nor respective bodies, executives, employees and advisers are under any shall it or any part of it nor the fact of its distribution form the basis obligation to update or keep current the information contained in this of, or be relied on in connection with, any contract therefor. This brochure or to correct any inaccuracies except to the extent it would brochure does not constitute a listing prospectus as defined in the be required under applicable law or regulation.
    [Show full text]
  • IMPORTANT NOTICE IMPORTANT: You Must Read the Following Before
    IMPORTANT NOTICE IMPORTANT: You must read the following before continuing. The following applies to the Prospectus following this page, and you are therefore advised to read this carefully before reading, accessing or making any other use of the Prospectus. In accessing the Prospectus you agree to be bound by the following terms and conditions, including any modifications to them any time you receive any information from us as a result of such access. NOTHING IN THE FOLLOWING PROSPECTUS CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. ANY SECURITIES TO BE ISSUED WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE U.S. OR OTHER JURISDICTION, AND THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE U.S. OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT). THE FOLLOWING PROSPECTUS MAY NOT BE FORWARDED OR DISTRIBUTED TO ANY OTHER PERSON AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS DOCUMENT IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS. Confirmation of your representation: In order to be eligible to view the Prospectus or make an investment decision with respect to the securities, investors must be non-U.S. persons (as defined in Regulation S under the Securities Act) outside the United States who are not acting for the account or benefit of U.S.
    [Show full text]
  • Board of Directors Curricula Vitae 2019
    ELECTIONS BOARD OF DIRECTORS CURRICULA VITAE Shareholder information on the elections at the Annual General Meeting 2019 ELECTIONS BOARD OF DIRECTORS Shareholder information on the elections to the Board of Directors at the Annual General Meeting 2019 LAFARGEHOLCIM 4 Annual General Meeting 2019 RE-ELECTIONS Beat Hess Chairman of the Board Professional background Swiss national born in 1949, Beat Hess is Chairman of the Board of Directors of LafargeHolcim Ltd. He was elected to the Board of Directors of LafargeHolcim Ltd (then “Holcim Ltd”) in 2010. He holds a doctorate in law and is admitted to the bar in Switzerland. From 1977 to 2003, he was initially Legal Counsel and subsequently General Coun sel for the ABB Group. From 2004 until the end of 2010, he was Legal Dire­ Beat Hess ctor and a Member of the Executive Committee of the Royal Dutch Shell Group, London and The Hague. His other mandates include that he is a Member of the Board of Directors, a Mem­ ber of the Chairman’s and Corporate Governance Committee, and Chairman of the Compensation Committee of Nestlé S.A., Vevey, Switzerland, as well as Vice­ Chairman and Member of the Nomination and Compensation Committee of the Board of Directors of Sonova Holding AG, Stäfa, Switzerland. He is also a Member of the Curatorium of the Hague Academy of International Law. Curricula Vitae Board of Directors 5 Paul Desmarais, Jr. Member Professional background Canadian national born in 1954, Paul Desmarais, Jr. is a Member of the Board of Directors and of the Nomination, Compensation & Governance Committee of LafargeHolcim Ltd.
    [Show full text]
  • Emtn Base Prospectus Dated
    IMPORTANT NOTICE IMPORTANT: You must read the following before continuing. The following applies to the Prospectus following this page, and you are therefore advised to read this carefully before reading, accessing or making any other use of the Prospectus. In accessing the Prospectus you agree to be bound by the following terms and conditions, including any modifications to them any time you receive any information from us as a result of such access. NOTHING IN THE FOLLOWING PROSPECTUS CONSTITUTES AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. ANY SECURITIES TO BE ISSUED WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE U.S. OR OTHER JURISDICTION, AND THE SECURITIES MAY NOT BE OFFERED OR SOLD WITHIN THE U.S. OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT). THE FOLLOWING PROSPECTUS MAY NOT BE FORWARDED OR DISTRIBUTED TO ANY OTHER PERSON AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS DOCUMENT IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS. Confirmation of your representation: In order to be eligible to view the Prospectus or make an investment decision with respect to the securities, investors must be non-U.S. persons (as defined in Regulation S under the Securities Act) outside the United States who are not acting for the account or benefit of U.S.
    [Show full text]
  • Protection Certificate on Lafargeholcim, Roche, Swiss Re, Swisscom, Zurich Insurance
    Termsheet Reference is made to any additional notification published separately COSI (Collateral Secured Instruments) Public Offering only in: CH Capital Protection Products SSPA Product Type: 1100 Collateralised Derivatives Protection Certificate on LafargeHolcim, Roche, Swiss Re, Swisscom, Zurich Insurance Protection Level below 90.00% - Autocallable Final Fixing Date 28/09/2022; issued in CHF; listed on SIX Swiss Exchange AG ISIN CH0187372294 - Swiss Security Number 18737229 - SIX Symbol EFGBPF This Product is collateralised in accordance with the terms and conditions of the SIX Swiss Exchange Ltd Framework Agreement for Collateral Secured Instruments. More detailed information regarding the collateralisation can be found in the section: "Information about Collateralisation" Investors should read the section “Significant Risks” below as well as the section “Risk Factors” of the relevant Programme. Investing in this product may put Investor’s capital at risk. Investor may lose some or all of its investment. Even though translation into other languages might be available, it is only the Final Termsheet and Programme in English which are legally binding. This Product is a derivative instrument according to Swiss law. It does not qualify as unit of a collective investment scheme pursuant to art. 7 et seqq. of the Swiss Federal Act on Collective Investment Schemes (CISA) and is therefore neither registered nor supervised by the Swiss Financial Market Supervisory Authority FINMA. Investors do not benefit from the specific investor protection provided under the CISA. The Investor's exposure to the credit risk of the Issuer and the Guarantor, if any, is only mitigated due to collateralization. This document is not a prospectus within the meaning of article 1156 of the Swiss Code of Obligations (CO) or article 40 et seqq.
    [Show full text]
  • Morningstar® Developed Markets Europe Moat Focus Indexsm 19 March 2021
    Morningstar Indexes | Reconstitution Report Page 1 of 3 Morningstar® Developed Markets Europe Moat Focus IndexSM 19 March 2021 The index follows a staggered rebalancing approach in which the index is divided into two sub-portfolios, each containing 25 stocks. One For More Information: sub-portfolio reconstitutes in December and June; the other sub-portfolio reconstitutes in March and September. The information here pertains http://indexes.morningstar.com only to the subportfolio being reconstituted. US: +1 312 384-3735 Europe: +44 20 3194 1082 Reconstituted Holdings Name Ticker Country Sector Moat Rating Price/Fair Value Weight (%) Imperial Brands Plc IMB United Kingdom Consumer Defensive Wide 0.46 4.00 Just Eat Takeaway.com NV TKWY Netherlands Consumer Cyclical Narrow 0.53 4.00 Bayer Motoren Werke AG (BMW) BMW Germany Consumer Cyclical Narrow 0.66 4.00 Vodafone Group VOD United Kingdom Communication Services Narrow 0.69 4.00 WPP Plc WPP United Kingdom Communication Services Narrow 0.70 4.00 Anheuser Busch Inbev NV ABI Belgium Consumer Defensive Wide 0.71 4.00 Continental AG CON Germany Consumer Cyclical Narrow 0.71 4.00 Danske Bank A/S DANSKE Denmark Financial Services Narrow 0.72 4.00 Roche Hldgs AG Ptg Genus ROG Switzerland Healthcare Wide 0.73 4.00 ConvaTec Group Plc CTEC United Kingdom Healthcare Narrow 0.79 4.00 Sanofi-Aventis SAN France Healthcare Wide 0.79 4.00 ING Groep NV INGA Netherlands Financial Services Narrow 0.80 4.00 Banco Bilbao Vizcaya Argentaria SA BBVA Spain Financial Services Narrow 0.80 4.00 Ubisoft Entertainment
    [Show full text]
  • Lafarge 2013 Annual Report
    ANNUAL REPORT REGISTRATION DOCUMENT LAFARGE 2013 LAFARGE PROFILE 44 SOCIAL AND ENVIRONMENTAL RESPONSIBILITY 11 4.1 Introduction .......................................................... 120 4.2 Building communities ........................................... 121 GROUP PRESENTATION 4.3 Building sustainably .............................................. 128 4.4 Building the circular economy ............................. 130 4.5 Key Performance Indicators ................................ 136 1.1 Lafarge presentation ............................................. 10 1.2 Strategy ................................................................... 12 1.3 Overview of operations ........................................... 28 55 RISKS AND CONTROL 22 5.1 Risks factor ........................................................... 146 5.2 Internal control procedures ................................. 158 OPERATING AND FINANCIAL REVIEW 5.3 Auditing matters ................................................... 162 AND PROSPECTS 2.1 Overview .................................................................. 44 2.2 Accounting policies and defi nitions ....................... 45 2.3 Results of operations for the years ended December 31, 2013 and 2012 ................................. 49 2.4 Liquidity and capital resources .............................. 57 66 SHAREHOLDERS, SHARE CAPITAL AND ADDITIONAL INFORMATION 6.1 Shareholders......................................................... 166 33 6.2 Share capital and additional information ............ 172 CORPORATE
    [Show full text]
  • Integrated Annual Report 2019 – Summary RECORD PERFORMANCE
    INTEGRATED ANNUAL REPORT ANNUAL INTEGRATED 2019 LafargeHolcim Ltd Integrated Annual Report 2019 – Summary RECORD PERFORMANCE CHF 26,722 m CHF 6,153 m +3.1% +6.5% Net sales¹ Recurring EBITDA (pre-IFRS 16)¹ 2018: CHF 27,466 m 2018: CHF 6,016 m CHF 3,047 m CHF 2,072m +79% +32 % Free Cash Flow (pre-IFRS16) Net income (pre-IFRS 16)² 2018: CHF 1,703 m 2018: CHF 1,569 m CHF 8,811 m CHF 3.40 –35% +29 % Net Debt (pre-IFRS16) Earnings per share (pre-IFRS 16)³ 2018: CHF 13,518 m 2018: CHF 2.63 561kg –5.7% Net CO₂ emitted per ton Reduction in freshwater withdrawn per ton of cementitious material (scope 1)⁴ of cementitious material ⁴,⁵ 2019: -1.4%⁴,⁵ 2019: 299 l 4.3% –15.2% Increase in waste reused in operations ⁴,⁵ Reduction in long-term injury frequency rate (LTIFR) ⁴,⁵ 2019: 48 million tons 2019: 0.67 ¹ Percentage change figures compare 2019 and 2018 on a like-for-like basis. ² Group share before impairment and divestments ³ Before impairment and divestments For more details on ⁴ Information on scope and methodology of data collection, as well as assurance on 2019 reported figures, can be any of the topics in this found in the Sustainability Performance Report on our website at www.lafargeholcim.com/sustainability. report, please visit: ⁵ At constant 2019 scope www.lafargeholcim.com RETURN ON INVESTED CAPITAL (%)¹ EARNINGS PER SHARE (CHF)² NET INCOME (CHFM) Before impairment and divestments Group share, before impairment and divestments 8.0 3.5 3.40 ² 2,500 7.6 ¹ 2,072 7.25 3.0 1,875 1,569 2.63 1,417 6.5 6.5 2.5 1,250 2.35 5.8 5.75 2.0 625 5.0 1.5 0 2017 2018 2019 2017 2018 2019 2017 2018 2019 ¹ Return on invested capital for 2019 ² Earnings per share before impairment and post-IFRS 16 is 7.4%.
    [Show full text]
  • Alcon Swiss Listing Prospectus
    Alcon Inc. (a stock corporation organised under Swiss law) Listing of 488,700,000 registered shares with a nominal value of CHF 0.04 each This document together with the attached Form 20-F (the “Form 20-F”) constitutes the listing prospectus (the “Listing Prospectus”) relating to the listing (the “Listing”) of 488,700,000 registered shares of Alcon Inc. (“Alcon” and, together with its consolidated subsidiaries, the “Alcon Group” or the “Group”) (the “Alcon shares”) in accordance with the International Reporting Standard of SIX Swiss Exchange Ltd (“SIX”). This Listing Prospectus is not an issue prospectus pursuant to article 652a of the Swiss Code of Obligations (Schweizerisches Obligationenrecht) (the “Swiss CO”). There will be no issue, public offering or other placement of Alcon shares in connection with the publication of this Listing Prospectus. This Listing Prospectus has been established solely for the purpose of the Listing and should not be relied upon for any other purpose. The Listing takes place in the context of the spin-off of Alcon. See “Item 4. Information on the Company—4.A. History and Development of the Company—The Spin-off” of the Form 20-F for further information. This Listing Prospectus does not constitute an offer to sell, or a solicitation by or on behalf of Alcon or Novartis of an offer to purchase or sell, Alcon shares or any securities of Novartis. The release, publication or distribution of this Listing Prospectus may be restricted by law in certain jurisdictions. No action has been or will be taken by Alcon or Novartis that would permit the possession or distribution of this Listing Prospectus in any jurisdiction where action for that purpose is required or doing so is restricted by law.
    [Show full text]
  • Elections Board of Directors
    ELECTIONS BOARD OF DIRECTORS CURRICULA VITAE Shareholder information on the elections at the Annual General Meeting 2018 ELECTIONS BOARD OF DIRECTORS Shareholder information on the elections to the Board of Directors at the Annual General Meeting 2018 LAFARGEHOLCIM 4 Annual General Meeting 2018 RE-ELECTIONS Beat Hess Beat Hess is Chairman of the Board of Directors of LafargeHolcim Ltd. He was elected to the Board of Directors of LafargeHolcim Ltd (then “Holcim Ltd”) in 2010. He holds a doctorate in law and is admitted to the bar in Switzerland. From 1977 to 2003, he was initially Legal Counsel and subsequently General Counsel for the ABB Group. From 2004 until the end of 2010, he was Legal Director and a Member of the Executive Committee of the Royal Dutch Shell Group, London and The Hague. His other mandates include that he is a Member of the Board of Beat Hess Directors, a Member of the Chairman’s and Corporate Governance Committee, and Chairman of the Compensation Committee of Nestlé S.A., Vevey, Switzerland, as well as Vice-Chairman and Member of the Nomination and Compensation Committee of the Board of Directors of Sonova Holding AG, Stäfa, Switzerland. Curricula Vitae Board of Directors 5 Paul Desmarais, Jr. Paul Desmarais, Jr. is a Member of the Board of Directors and a Member of the Nomination, Compensation & Governance Committee of LafargeHolcim Ltd. He was elected to the Board of Directors of LafargeHolcim Ltd in 2015. He holds a Bachelor of Commerce from McGill University, Montréal, Canada, and an MBA from the European Institute of Business Administration (INSEAD), Paris, France.
    [Show full text]